The Nobel Prize-winning discovery of streptomycin has enabled the treatment of several infectious diseases, including tuberculosis (TB). Since then, many newer antibiotics have been combined into anti-TB drug treatment regimens that have saved millions of lives. However, despite advances in the past, until the emergence of SARS-CoV-2, TB was the leading cause of infectious disease mortality worldwide, with more than 1 million deaths annually.

Although the current standard treatment for TB is effective, it is also unwieldy. Patients with uncomplicated drug-susceptible TB are required to take multiple antibiotics for 6 months. Since compliance is inconsistent, WHO recommends that this be directly supervised, adding an enormous layer of infrastructure to an exceptionally long treatment programme. With the rise of drug resistance, treatment failure rates have increased along with more toxic therapies that are far more costly.

Improved interventions could have a substantial effect on our ability to decrease the morbidity and mortality associated with the disease and to limit further spread, as treatment of active TB is the major modality for preventing transmission in most of the world.

We are at an exciting juncture in TB regimen development. For the first time in four decades, a 4-month regimen, containing rifapentine and moxifloxacin, was found non-inferior to the standard 6-month regimen in the treatment of drug-susceptible TB at the 12-month follow-up. In 2019, the first 6-month regimen was approved for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, comprising only three drugs with two novel mechanisms of action: bedaquiline, pretomanid and linezolid. Yet, shorter, better tolerated and more successful treatments are needed for all patient populations. Accomplishing this will require both new antibiotics and new combinations of approved drugs and clinical candidates.

Compared to a decade ago, the anti-TB drug pipeline is in healthy shape with both repurposed and repositioned antibiotic classes as well as drug candidates that act via novel mechanisms of action (Working Group on New TB Drugs). Because of this success, the most important research focus has become the prioritization of promising drug regimens. Although there is a considerable amount of active research and development in this area, one major limitation is the lack of validated in vitro and animal models that predict the success of drugs and drug combinations.

Here, we discuss the uneven distribution of TB burden and disease spectrum around the world and its implication on treatment strategies and challenges. We review new technological advances in mycobacteriology, their impact on TB drug discovery and development, and where knowledge gaps remain. Basic and preclinical research priorities are proposed to accelerate the development of curative drug regimens. Not included here are a survey of host-directed therapy approaches, an exhaustive summary of clinical drug candidates and their targets, nor...
a list of clinical trials of single drugs and drug regimens, all recently and comprehensively reviewed elsewhere3–5.

**TB burden and spectrum of disease**

**Burden distribution and inequalities.** TB disease is proceeding asynchronously around the world. In 2019, 30 countries with a high TB burden accounted for 87% of new TB cases and 8 countries accounted for two-thirds of the total cases (WHO tuberculosis)4. As disease burden is strongly associated with socio-economic conditions5, its incidence rates have different trajectories in different parts of the world. In the USA, TB has an incidence similar to amyotrophic lateral sclerosis; in other words, it is a very rare condition. China and the Russian Federation
formerly suffered from high TB rates but, although still incurring substantial burden, they are on a better trajectory than most high-burden countries (Fig. 1). In other parts of the world, such as in South America, North Africa and parts of Asia, where incidence was moderate a few decades ago, the TB–diabetes syndrome has reverted the trend; diabetes being an important risk factor for developing TB and presenting more complicated disease, higher relapse rates and mortality. Although several comorbidities can increase susceptibility to TB, HIV-1 is the leading determinant of reactivation risk and thus contributes to the TB burden in sub-Saharan Africa. The long-term repercussions of the COVID-19 pandemic combined with wealth inequalities will further widen the divide. To a large extent, distinct regions and sub-continents face unique challenges that require tailored improvements in diagnostic and treatment strategies. Yet, treatment guidelines, diagnostics and research needs tend to be defined globally, based on the integration of worldwide statistics.

**Spectrum of disease.** WHO defines latent TB infection (LTBI) as a state of persistent immune response to stimulation by *Mycobacterium tuberculosis* antigens without evidence of clinically manifested active TB and with bacillary replication absent or below some undefined threshold as a result of immunological control. LTBI affected approximately 1.7 billion individuals in 2014, just under one-quarter of the global population. The rate and risk of LTBI reactivation are greatest within 2 years from infection, then decline from 2 to 5 years and beyond. Quantifying the rates of late reactivation versus early progression is complicated by reinfecction in high-incidence areas and difficulties in validating starting assumptions such as the presumption that asymptomatic infection is lifelong. The substantial gaps that remain in our understanding of reactivation hinder our efforts towards TB eradication as the burden of LTBI constitutes an enormous reservoir from which active TB cases can emerge. Identifying and triaging this population will drive our chances to meet the global targets of 90% reduction in TB incidence by 2050 and elimination of TB (less than 1 incident case per 1,000,000 per year) by 2050.

Active pulmonary TB disease either appears within 1–2 years after infection or following reactivation of latent infection in ~5–15% of infected individuals throughout their lifetime. TB disease is defined by progressive bacterial replication and pulmonary necrosis and often but not always includes cavitary lesions that promote the transmission of bacteria. Although the outcome of infection by *M. tuberculosis* has generally been represented as a bimodal distribution between active and latent TB based on the presence or absence of clinical symptoms, it is now increasingly viewed as a continuous spectrum generated by a varied immunopathology that supports bacterial replication, persistence or killing, extending to within-host heterogeneity.

The current drug regimen used to treat uncompli- cated drug-susceptible TB is the outcome of several decades of clinical trials. This short-course therapy with isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months followed by 4 months of isoniazid and rifampicin was implemented four decades ago and has not changed since. By contrast, numerous clinical trials of drug-resistant TB were recently completed or are recruiting, providing a dynamic landscape and opportunities to improve cure rates and reduce therapy duration from 24 to 6 months. The mandate of major drug discovery initiatives is to develop drugs that, in combination, create shorter, safer and simpler regimens to cure all patients with TB.

The possibility that isoniazid could be used to prevent reactivation of LTBI was considered soon after it was introduced in 1952. Subsequent clinical trials in the 50s and 60s demonstrated a marked reduction in active TB in patients treated with isoniazid and a long-lasting protection. Based on these results, preventive treatment of TB infection with isoniazid for 6 or 9 months became a widespread approach to TB control and is still in use today. More recently, a rifamycin was added to or substituted for isoniazid, which successfully reduced treatment duration. Five regimens of various durations that include isoniazid and/or a rifamycin are recommended globally and considered equivalent by measure of effectiveness and hepatotoxicity, though they have not been directly compared in clinical trials. Besides historic trials with pyrazinamide, levofloxacin in children and adults and delamanid (PHOENIX MDR-TB) are currently being tested as prophylactic therapy in household contacts of patients with MDR-TB.

TB infection and disease present as a multifaceted spectrum that can be represented in three dimensions (see below). LTBI is now recognized as a dynamic continuum of response to infection. At the ‘active’ end of the latency spectrum are individuals at high risk of developing active disease (‘progressors’), who would benefit from reactivation risk assessment and treatment. Identifying and curing this population is critical to meet the global targets for TB control and elimination by 2050. The spectrum of LTBI, from true latency to incipient disease, has been comprehensively reviewed elsewhere. Due to the lack of validated immune and bacteriological markers, LTBI is only operationally defined as a state of persistent immune response to stimulation by *M. tuberculosis* antigens without evidence of
clinically manifested active TB, hampering the triaging of those at greatest risk for progression to TB disease. Overall, basic knowledge gaps are deeper for LTBI than for active disease.

Active symptomatic TB presents with a range of severity, primarily classified as either cavitary disease or moderate non-cavitary disease. Decades of clinical trials consistently point towards poorer prognostic and treatment outcomes for cavitary disease. Recent retrospective analyses have shown that patients with cavities and a high bacterial burden in sputum may require treatment durations of more than 6 months, whereas 4-month therapy was non-inferior to 6-month therapy in patients with non-cavitary minimal disease. The identification of patients who might benefit from shorter treatment durations could therefore only require broadly available chest X-ray radiography and sputum smear methods.

Fig. 2 | TB infection, disease spectrum and associated challenges. Tuberculosis (TB) presents as a spectrum along three axes: disease pathology and severity, bacterial persistence and drug tolerance, and genetic resistance. The pathology of TB disease is a dynamic continuum from fully latent asymptomatic infection to active disease with high bacterial burden in open cavities, leading to transmission and more frequent treatment failure. Individuals with latent TB infection who are progressing towards incipient TB are at high risk of developing active disease and would benefit from reactivation risk assessment and treatment. The spectrum of immunopathology creates a diversity of microenvironments to which the pathogen responds with metabolic and physiological adaptations leading to drug tolerance or phenotypic drug resistance and persistent disease. Drug tolerance as well as other patient and pathogen factors lead to a spectrum of genetic resistance both in terms of the number of drugs a bacterium is resistant to and the level of resistance to each drug. Such variability along three axes creates a gradient of decreased drug efficacy and lesion sterilization within and across patients, constitutes a multidimensional challenge for health-care programmes and complicates clinical trials.

Cavitary disease
Active disease characterized by the presence of open pulmonary cavities in the lung parenchyma, composed of a wall filled with necrotic debris and high bacterial burden, leading to poor treatment outcome and increased person-to-person transmission.
Drug tolerance

Increased survival of bacterial cells in the presence of drug, generally not driven by genetic mutations but due to physiological or metabolic adaptations that lead to decreased growth rate upon encountering specific environmental conditions.

Persistor subpopulation

The subpopulation of bacteria that survives the bactericidal action of antibiotics but is genetically identical to susceptible bacteria and appears to be non-replicating or slowly growing in response to various stresses.

Treatment of drug-susceptible and drug-resistant \textit{M. tuberculosis} strains requires a minimum of three to four antibiotics in combination, leading to complex patterns of drug susceptibility and resistance. The infecting \textit{M. tuberculosis} strain is classified as fully drug susceptible, mono-resistant, MDR or XDR. Within the latter two categories, individual drug susceptibility profiles guide the design of patient-tailored drug regimens, which are subject to national guidelines and institutional policies\textsuperscript{64,65}.

In both LTBI and active disease, host immunity produces diverse microenvironmental niches that support suboptimal growth or complete growth arrest of \textit{M. tuberculosis}. Many different lesions, with different immune effects, exist simultaneously in a single infected individual. The physiological state of non-replication in bacteria is associated with drug tolerance or phenotypic drug resistance. Indeed, the response to drug treatment is biphasic, with an initial phase of rapid though incomplete clearance of the bulk of infecting bacilli, followed by a longer phase required for complete sterilization of persisting populations\textsuperscript{66}. In a defined bacterial population, drug tolerance is either induced by a variety of stresses or is conferred by pre-existing physiological heterogeneity\textsuperscript{67–69}, both producing a persistor subpopulation. Cell-to-cell variability creates an almost infinite spectrum of phenotypically heterogeneous subpopulations even under uniform conditions\textsuperscript{10–15}, which is thought to ensure survival, as at least a small proportion of cells are predisposed to respond to potential threats such as antibiotics, a strategy coined as ‘bet-hedging’\textsuperscript{70}. Cell-to-cell heterogeneity is viewed as the consequence of both stochastic noise and specific regulatory systems that couple cell cycle progression and adaptive bacterial metabolism with changing host-associated environmental stress. Inclusion of adaptive regulatory elements to the stochastic noise mechanism for the generation of phenotypically diverse bacteria within a population has led to a concept referred to as ‘phenomic potential’\textsuperscript{71}. The phenomenon of drug tolerance is particularly acute at the sites of TB disease and is a hallmark of the disease as well as a major factor contributing to protracted therapy duration due to long-standing host–pathogen co-evolution\textsuperscript{72} and the resulting adaptations of \textit{M. tuberculosis} in response to host immunity. There is broad consensus that phenotypic drug resistance contributes to individual variability in TB disease persistence\textsuperscript{73}, relapse and reactivation. However, large knowledge gaps remain to determine how in vitro observations of these phenomena can be applied to predict clinical outcome. In the following section, we explore the treatment challenges that are associated with disease complexity.

Treatment challenges

Treatment of all forms of active TB disease requires multiple antibiotics administered for several months\textsuperscript{74}. Approved first-line, second-line and third-line agents recommended to treat drug susceptible, MDR and XDR TB, respectively, are listed in Supplementary Table 1. The variability of disease progression, host response and drug resistance phenotypes complicates treatment and drug discovery but also creates opportunities to stratify patient populations and optimize preventive and therapeutic strategies. Because TB is largely a disease that occurs in resource-constrained countries, existing infrastructure only enables moderately complex interventions. This adds substantial operational and implementation challenges to the already daunting research mandate.

Identifying individuals with LTBI at high risk of reactivation. Currently, the WHO recommends preventive treatment for individuals with LTBI who are at high risk of TB reactivation; that is, people living with HIV-1, infants and children under 5 years of age who are household contacts of patients with pulmonary TB, and patients who receive immunosuppressive therapy\textsuperscript{32–34,39}. Scientific breakthroughs have recently made it possible to identify patients at risk of reactivating LTBI based on immunobiology rather than on the mainly operational criteria described above\textsuperscript{41}. These include non-invasive positron emission tomography–computed tomography (PET–CT) and PET–magnetic resonance imaging (PET–MRI), immune response markers identified by transcriptomics\textsuperscript{42} and other omics approaches, genome-wide association studies of host and pathogen, epigenetics, and the identification of differentially expressed genes in individuals who control LTBI and progressors in both patients and animal models (Supplementary Table 2). However, validation studies are needed to determine the utility of biomarkers in estimating the size of mycobacterial burden, and markers of protective immunity as surrogates of incipient TB\textsuperscript{43}. Although some of these approaches are not compatible with the capacities in resource-poor countries, they critically contribute to our knowledge of reactivation and can form the basis for the development of surrogate markers adapted to the global health realities where TB burdens are highest. Once predictive markers are validated in prospective clinical studies, implementation hurdles will remain to translate ‘high risk’ determination into appropriate treatment of potential progressors\textsuperscript{44}. This is further compounded by the caveats of current preventive therapy: the lack of a universal regimen active against drug-resistant \textit{M. tuberculosis}\textsuperscript{45}, the hepatotoxicity\textsuperscript{65} and limited sterilizing activity of isoniazid\textsuperscript{46}, drug–drug interactions between rifamycins and anti-retroviral therapy\textsuperscript{75}, and poor acceptance and completion rates globally\textsuperscript{46}. Moreover, adding LTBI therapy to current TB treatment programmes will be a logistical challenge. However, the CDC does currently recommend treatment for every infected individual regardless of the risk of reactivation. The preferred regimens are identical to those recommended by WHO; three rifamycin-based regimens and two alternative monotherapy regimens with daily isoniazid, unless the infecting \textit{M. tuberculosis} strain is presumptively resistant to both isoniazid and rifampin\textsuperscript{47}. This treatment approach is manageable within the USA and, perhaps, other countries with either low or moderate prevalence of LTBI.

Assessing disease severity of patients with active TB. Cavitation status and bacterial burden in sputum are consistently emerging as correlates of disease outcome\textsuperscript{42,43}. According to the current American Thoracic Society/CDC/Infectious Diseases Society
of America Clinical Practice Guidelines, therapy for 9 months is recommended to treat extensive cavitary TB as well as for patients with positive sputum cultures persisting at 2 months. Extended treatment duration is also considered for patients with low body mass index, smokers, individual with diabetes, and individuals with HIV-1. Recently, an in-depth analysis of clinical trial data has revealed that patients with non-cavitary TB, infected with drug-susceptible \textit{M. tuberculosis} and with a low sputum burden could successfully complete therapy within 4 rather than 6 months. This opens up the possibility for a stratified approach that would tailor treatment duration based on initial disease severity (high bacterial burden in sputum and cavitary disease) as an alternative to the standard 6-month duration for treatment. Shortening treatment when appropriate would improve completion rates and provide welcome relief to health-care systems. Markers such as presence of cavities and bacterial load in sputum can be assessed in resource-limited settings and could be rapidly validated if their correlation with treatment duration were systematically integrated in clinical trials. Pending formal validation, the remaining challenge is the implementation of new flexible treatment guidelines on a global scale given burden inequalities and unique treatment challenges in distinct regions and subcontinents.

\textbf{Understanding drug tolerance.} Targeting drug-tolerant bacterial populations and persisters is the key to achieving faster durable cure. These populations drive the drug recalcitrant nature of both active disease and LTBI. As a research community, we have a good understanding of the microenvironments and stress conditions that exist at the site of disease, but there remain uncertainties about the clinical relevance of each one and how they influence treatment outcome. We have developed assays that reproduce conditions of immune pressure and environment as well as drug-induced stress, in vitro and ex vivo, and we understand how \textit{M. tuberculosis} adapts to these conditions and how this translates to reduced drug susceptibility in these models (Table 1). Ex vivo models, such as those relying on explanted cavity casem from rabbits and differentially culturable \textit{M. tuberculosis} retrieved from patient sputum, most faithfully reproduce in vivo conditions but are inherently resource intensive and mostly suitable to profile approved drugs and clinical development compounds. Drug tolerance of intracellular \textit{M. tuberculosis} remains a substantial knowledge gap for two reasons. First, a wide range of immortal cell lines and, occasionally, macrophages derived from primary blood or bone marrow monocytes are used for \textit{M. tuberculosis} infection assays, leading to discrepant potency values. For example, \textit{M. tuberculosis} is approximately 100-fold less susceptible to rifampicin within hypoxic lipid-loaded macrophages than in normoxic THP-1-derived macrophages, yet macrophage-like immortalized cell lines are commonly used due to their low cost and ease of maintenance considerations. A comparative review of anti-TB drug potency within infected primary macrophages and common cell lines is lacking. Second, polymorphonuclear leukocytes are increasingly recognized as a crucial and permissive niche of bacterial survival and replication. Rather than eliminating mycobacteria, neutrophils seem to provide a safe haven and transport mycobacteria to macrophages while they retain the potential to damage host tissue. To date, no in vivo or ex vivo assay has been developed to assess the drug tolerance of \textit{M. tuberculosis} residing within and around neutrophils and other granulocytes. Although the short lifespan of neutrophils may present a challenge, a recent study showed that granulocytes are retained in \textit{M. tuberculosis}-infected mouse lungs at least as long as monocytes and macrophages, consistent with a model in which \textit{M. tuberculosis} uses granulocytes as a replicative niche for intracellular growth.

In vivo, we have optimized a wide range of animal models, none fully reproducing human TB, but each with features justifying its utility (Supplementary Table 3). It has been suggested that TB should be approached as a polymicrobial infection. Human infection may consist of replicating, dormant (slow-growing or non-growing) and reactivated bacteria in all clinical stages. The relative proportions of these cells may change in response to host immune responses and antibiotic therapy. In other words, the range of phenotypic antibiotic susceptibility in a population is extreme, possibly exceeding that seen for genetic variants. Filling the knowledge gaps to achieve treatment shortening can thus be viewed as a two-step process: first, the inventory of available assays and models that collectively recapitulate micro-environmental conditions encountered in vivo and produce all potentially relevant pathophysiological states of the bacteria, validation of in vitro assay panels that predict clinical treatment shortening, and determination of which animal models are required to bridge in vitro assays and clinical efficacy for new drug candidates; second, the identification of missing assays, models, and bacterial profiles to refine the predictive power of the approach and determination of how they integrate within a patient to drive treatment outcome (that is, the response to treatment may be more complex than the sum of its parts, even if, collectively, assays and models faithfully capture all relevant in vivo conditions). Many have thought that the best way to identify successful therapies is to find agents active in all assay conditions; however, this might well not be true. Prioritizing in vitro assay conditions that have been validated as predictive of in vivo and clinical treatment is likely to yield better drug candidates and help focus resources. Though challenging, all this seems attainable with the ever-faster development of new technologies and a healthy drug pipeline.

\textbf{Determining high risk of recurrence following therapy completion.} Rather than complete bacterial eradication in all treated individuals, apparent bacterial sterilization during and following TB chemotherapy is now understood to include an antibiotic-induced persistent state that forms a relapsing reservoir in a subset of treated patients. Accordingly, “high resolution” determination of the minimum inhibitory concentration (MIC) of isoniazid and rifampicin within the drug-susceptible range (that is, below standard resistance breakpoints) has shown that higher MIC values were associated with a greater risk of relapse than lower MIC values. We lack validated

Minimum inhibitory concentration (MIC). The lowest drug concentration that inhibits growth.

Resistance breakpoints
The minimum inhibitory concentration (MIC) above which an antimicrobial agent is considered to have a low probability of treatment success in the clinic.
Table 1: Selected potency assays to reproduce microenvironments of pulmonary tuberculosis

| Microenvironmental condition replicated in each assay | Assay and model | Replication status | Drug tolerance | Strength | Limitation | Refs |
|-------------------------------------------------------|----------------|-------------------|---------------|----------|------------|------|
| Replicating culture¹                                | Standard minimum inhibitory concentration and minimum bactericidal concentration assays | Replicating | NA | Baseline reference assays | Baseline reference assays | 156 |
| Nonspecific conditions that induce dormancy          | Streptomycin-addicted strain SS18b | Non-replicating | Drug class specific (SS18b mostly tolerant to cell wall inhibitors) | Requires no special equipment; SS18b can be used in vivo to simulate latency in animal models | Induction of dormancy is non-physiological | 157 |
|                                                      | Late stationary phase (30 to 100 days old) culture, can be grown microaerophilically | Non-replicating | High but likely to be heterogeneous | Simple, requires no special equipment | Bacterial population is highly heterogeneous and asynchronous in late stationary phase, which affects reproducibility | 156,159 |
| Acidic pH                                            | pH 4.5–6 in standard growth medium | Slow-replicating tonon-replicating, pH dependent | Variable from sensitization to tolerance, drug specific | Amenable to high-throughput screening | Acidic pH can either sensitize Mycobacterium tuberculosis to drug action or induce drug tolerance; acidic pH affects M. tuberculosis growth below pH 5.8 and may affect drug stability | 156,158 |
| Acidic pH with host lipids                           | pH 4.5–5.5 with oleic, palmitic, arachidonic acid and/or cholesterol added | Replicating (M. tuberculosis can grow at pH as low as 4.5 in the presence of host-relevant lipids) | Moderate to high | Integrates lipid utilization as a target and as a source of drug tolerance; mitigates the limitation of the acidic pH-only assay | Media preparation includes poorly soluble long-chain fatty acids | 162 |
| Nutrient deprivation and/or carbon starvation        | Loebel cidal assay in PBS or carbon starvation assay in standard media lacking carbon source | Non-replicating | High (carbon starvation) to very high (PBS) | M. tuberculosis isolated from lung lesions has an altered morphology and reduced acid-fast staining similar to M. tuberculosis starved in PBS in vitro; amenable to high-throughput screening with a recovery phase | Does not reproduce physiological conditions typically encountered at the sites of disease | 165–166 |
| Oxygen starvation                                    | Low oxygen recovery assay | Non-replicating followed by recovery for 28 h | Moderate to high | Adequate for high-throughput screening | Recovery phase is sensitive to drug carryover through absorption to the bacterial surface | 167 |
|                                                      | Wayne cidal oxygen depletion assay | Non-replicating | High | Low-oxygen tension is encountered in necrotic lesions and is a key driver of non-replication and dormancy through DosR and induces drug tolerance | Low-throughput resource intensive assay | 83,166–170 |
| Lipid-rich and cholesterol-rich niches               | Fatty acids (typically butyrate) or cholesterol as carbon source in standard growth medium | Replicating to slow replicating | Low to moderate | Reproduces the lipid-rich environments M. tuberculosis encounters in foamy macrophages and necrotic lesion foci, leading to accumulation of intrabacterial lipid inclusions and pronounced drug tolerance | Assays do not reproduce the complex mixture of triacyl glycerides, fatty acids, cholesterol and cholesterol esters found in macrophage lipid droplets and in caseum | 74,96,171–174 |
| Lipid-rich and acidic niche                          | Host-relevant lipids (long-chain fatty acids and cholesterol) at pH 4.5 | Slow replicating | ND | Shift from glycerol or glucose to long-chain fatty acids and/or cholesterol as carbon source supports growth at pH 4.5; amenable to high throughput screens | Assay does not reproduce the complex lipid mixture found in lipid droplets and in caseum | 162 |
markers to follow treatment response and distinguish, in real time, patients who need to remain on treatment from hyper-responders who can complete treatment earlier. Identifying patients who might require longer-than-standard treatment duration would minimize costly relapses. A five-gene signature that correlates with the pulmonary inflammatory state, as measured by PET–CT, identified patients at risk of treatment failure 1–4 weeks after start of therapy. More recently, a 22-gene transcriptomic model that predicts cure-associated end-of-therapy was defined for patients infected with drug-susceptible and MDR *M. tuberculosis* strains. Developing rapid and affordable point-of-care tests that quantify these biomarkers and deploying assays and adapted treatment guidelines are the major unmet needs.

**Simplifying and improving treatment of drug-resistant disease.** The clinical drug candidate pipeline is healthy, enabling a shift in favour of developing pan-TB or

| Microenvironmental condition replicated in each assay | Assay and model | Replication status | Drug tolerance | Strength | Limitation | Refs |
|--------------------------------------------------------|-----------------|-------------------|----------------|----------|------------|------|
| Macrophages and phagolysosomes | Multi-stress model: acidic pH, mild hypoxia, reactive nitrogen intermediates, fatty acid carbon source (and combinations thereof) | Non-replicating (can be followed by recovery and outgrowth to deconvolute compounds active against replicating versus non-replicating bacteria) | High | Clearly defined conditions that facilitate reproducibility; combines major growth-restrictive conditions encountered in the phagolysosome; a stress deconvolution scheme has been proposed | The four stresses omit other relevant conditions that could limit *M. tuberculosis* replication and induce tolerance; butyrate is the sole lipid carbon source | 48,175 |
| Intracellular growth inhibition assay | Replicating or slow replicating | Low to moderate | Has the potential to reproduce native conditions found in macrophages in vivo, if primary macrophages found in infected lungs are used | Substantial assay variability associated with macrophage type; less clinically relevant immortal cell lines such as THP-1 or J774 are used rather than primary activated foamy macrophages for practical reasons; results are sensitive to minor assay differences and a comparative review appears to be lacking | 143,176,177 |
| Cavity caseum | Explanted rabbit caseum assay without aeration to simulate decreasing oxygen gradient | Non-replicating | High | Closest to native caseum conditions | Low-throughput and resource intensive; variable cavity-to-cavity starting burden | 72 |
| Biofilm-like aggregates | Multiple formats such as pellicles at the air–medium interface and attached microbial communities on lysed leukocytes | Both replicating and non-replicating phases are amenable to drug potency measurements | Generally high | *M. tuberculosis* biofilm-like structures form spontaneously at the air–medium interface; the model can be exploited to understand the basis of biofilm-associated antibiotic tolerance | The existence of bona fide *M. tuberculosis* biofilms in patients remains a matter of debate; they may be better described as ‘attached communities’; assay formats vary widely, which challenges reproducibility | 176–180 |
| Sputum | Most probable number assay using ex vivo sputum cells to quantify effect of drug treatment on differentially culturable *M. tuberculosis* with and without resuscitation | Non-replicating | Variable and subpopulation specific | Highly clinically relevant; reveals drug tolerance of three differentially culturable bacterial populations found in human sputum: forming colonies on plate, growing in liquid medium only without resuscitation, or growing in liquid medium only with prior resuscitation using culture filtrate | The assay is logistically complex with very few laboratories set up to perform it; result interpretation is confounded by potential subpopulation overlap and transition between the three states upon drug treatment | 53,171,181 |

NA, not applicable; ND, not determined; PBS, phosphate-buffered saline. *Most widely used in the field. Dormancy models are reviewed in REF. 192.* Listed as reference assays to determine baseline potency under replicating conditions in standard growth medium.

---

**Table 1 (cont.) | Selected potency assays to reproduce microenvironments of pulmonary tuberculosis**

| | | | | | | |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
universal drug regimens to treat all forms of drug-susceptible and drug-resistant TB. The success of the NIX-TB trial (NCT02333799), a 6-month three-drug regimen that delivered high cure rates in select patient populations infected with MDR and XDR strains, constitutes a promising step towards this aspirational goal. New diagnostic tools that either simplify or increase the accuracy of drug-resistance profiling are continuously improved to help physicians and health services interpret results and provide faster and more targeted treatment for patients. Recently, the WHO published a catalogue of 17,000 M. tuberculosis mutations and their association with drug resistance. The report provides a reference standard for the interpretation of mutations conferring resistance to all first-line and a variety of second-line drugs. It complements an elegant tool called SplitStrains, which leverages whole-genome sequencing data to identify and separate mixed M. tuberculosis infections with genetically different strains, a phenomenon that can lead to hetero-resistance and the ensued treatment complications. The new toolkit enables more precise detection, identification and quantification of multiple infecting strains within a sample. Besides the implementation of new improved diagnostics, the major challenge to eradicate drug-resistant TB is the discovery and development of universal regimens only comprising drugs with novel mechanisms of action and minimum side effects, which would not only be used to treat resistant TB but could also replace the first-line regimen. Towards this goal, the Tuberculosis Drug Accelerator was launched in 2011 as an experiment designed to facilitate collaboration in anti-TB drug discovery by breaking down barriers among competing laboratories and institutions. The Tuberculosis Drug Accelerator is a unique collaboration of academic, pharmaceutical, global non-governmental organizations and governmental organizations that pledge to make medicines affordable to those in need, build knowledge and seek to develop shortened, less toxic, universal drug regimens that can achieve rapid, durable cure irrespective of resistance to existing drugs.

Drug development priorities

The shortcomings of TB treatment can be ascribed to four major challenges: curing TB takes considerably longer than any other bacterial infection of the lungs owing to a combination of drug, pathogen and host factors; drug tolerance fuels and synergizes with drug resistance; single drug and regimen development tested in sequence is inherently slow while tools are emerging to rationally prioritize regimens early in the cascade; and a surprisingly small number of drugs have been tested as preventive therapy of LTBI. Although the division into such broad areas may appear overly schematic, it provides a useful starting point to highlight where future research could focus and identify drug development priorities.

Addressing biological knowledge gaps to optimize treatment. Persistent TB disease is a consequence of immune evasion or the ability of M. tuberculosis to persist and multiply within the very host cells committed to eliminating bacterial pathogens, suboptimal drug penetration at the sites of disease, and extreme drug tolerance of selected subpopulations, some located in necrotic granulomas and cavity caseum. Such niche-specific pharmacokinetics and pharmacodynamics present a challenge to ensure optimal drug delivery to bacilli in dynamic physical loci and metabolic states.

Host-directed approaches that complement antibacterial therapy to accelerate cure generally rely on four major concepts: modulation of pro-inflammatory mediators to dampen inflammation, curb immunopathology and improve lung function and integrity; enhancement of immune and memory response efficacy; enhancement of macrophage and neutrophil bactericidal mechanisms to counter the immune evasion mechanisms of M. tuberculosis; and disruption of granuloma structure to improve drug penetration and expose the bacilli to drug action. These approaches and corresponding therapies in clinical development are beyond the scope of this Review and have been comprehensively reviewed in recent years.

A multipronged strategy centred on the pathogen, its metabolic and physiological adaptations, its precise location relative to immune cells and lesion structures, and its susceptibility to drugs and drug combinations in these niches will certainly increase our understanding and might contribute the knowledge required to develop shorter regimens. Recent efforts have focused on the identification of mycobacterial targets that are essential and vulnerable in persistence niches: sputum infected mouse lungs, ex vivo and in vitro macrophages, and other relevant environments (reviewed in Ref.). Although host transcriptome analyses are widespread and deliver increasingly robust data, the very low abundance of pathogen transcripts relative to host transcripts in biological samples constitutes a formidable challenge and a limitation of currently available technologies. However, this hurdle is likely to be overcome soon given the ever-improving performance of sequencing platforms and big data analysis. Multi-omics profiling of M. tuberculosis in caseous, foamy hypoxic macrophages, neutrophils and other persister populations in specific lesion compartments will identify pathways and functions that are critical to mycobacterial survival and might represent new antibiotic targets, thus possibly enabling shortening treatment duration. Likewise, a proven CRISPR interference-based functional genomics screen could be applied to persistence environments, such as ex vivo caseum, macrophages and mouse infections, to identify vulnerable targets as well as targets that synergize or antagonize drug treatment.

Leveraging the potential of synergistic drug interactions in multdrug treatment regimens to accelerate durable cure is a growing field that successfully combines experimental, systems biology and computational tools in powerful platforms such as INDIGO and DiaMOND. Collectively, they constitute a living repository of drug interactions on which researchers can build to refine their predictive value. However, although screening for positive and negative drug interactions in vitro is straightforward, understanding which model systems and in vitro assays predict synergies that...
might translate into the clinic is complex because TB is a polymicrobial disease spread across multiple sites of infection, whereas in vitro synergies are measured in a homogeneous environment using constant drug concentrations. Stochastic and adaptive cell-to-cell bet-hedging leading to a selective advantage for the whole bacterial population is likely to contribute to synergy and antagonism in ways that may be difficult to reproduce in vitro\(^\text{95}\). As a promising example, treatment with bedaquiline in vitro activates a regulatory network that coordinates multiple mechanisms to push \(M.\) \(tuberculosis\) into a tolerant state, which can be disrupted by knocking out its predicted transcription factors Rv0324 and Rv0880, increasing bedaquiline killing\(^\text{108}\). This finding enabled the prediction that pretomanid could synergize with bedaquiline through inhibition of the Rv0880-response regulon and potentiate killing by bedaquiline at the population level. Although the authors experimentally confirmed the predictions in vitro, identifying bacterial populations to which this applies in animal models and in patients with TB is the critical next step for bedaquiline–pretomanid as the backbone of the highly successful NIX–TB regimen\(^\text{7}\) and for all predicted drug–drug synergies in general. In vitro models, such as INDIGO, are pathway based, enabling the formulation of hypotheses to test the underlying biological mechanisms and adjust in vitro growth conditions to improve predictions. Recently, the predictive power of the DiaMOND platform was evaluated using drug combination dose responses measured under eight conditions that reproduce lesion microenvironments. Machine learning was applied to all two-drug and three-drug combinations of ten antibiotics to develop classifiers predictive of multidrug treatment outcome in a mouse model of disease relapse\(^\text{109}\). Identifying positive pharmacodynamics interactions in vitro that translate into the clinic is further complicated by the fluctuating drug concentrations seen by bacilli at the sites of infection as potency interactions inherently depend on the relative concentration of each drug in the combination. To better realize the potential of combination therapy, an interaction landscape is drawn over the full dose–response matrix to delineate synergistic and antagonistic dose regions and quantify the interactions. These can then be mapped back to the in vitro–in vivo correlation to refine in vivo predictions.

Elegant tools exist, and many more are developed, to probe the heterogeneity of bacterial behaviour inside the host niche, survey their metabolic state, and track them during therapy in animal models\(^\text{49,109,110}\) and inpatient bioaerosols\(^\text{111}\). One key pragmatic outcome of these activities is the detection and mapping of \(M.\) \(tuberculosis\) persister that survive drug treatment, which would guide prioritization of future research. Validation of the findings from samples of the human lung is challenging although resected lung tissues from patients undergoing elective surgery for drug refractory disease may be an underexploited resource. As mentioned earlier, the contribution of \(M.\) \(tuberculosis\) bacilli that survive and multiply in and around neutrophils to persistent disease\(^\text{80,27,28}\) has been largely underestimated, overshadowed by the role of macrophages, which are much more amenable to in vitro and ex vivo studies. However, in sputum and cavity caseum, \(M.\) \(tuberculosis\) bacilli are primarily extracellular or within neutrophils, with a smaller fraction replicating in macrophages\(^\text{57}\). Consistent with these observations, a signature of active TB is dominated by a neutrophil-driven interferon-inducible gene profile\(^\text{112}\) and cavity caseum is often infiltrated with infected neutrophils in both animal models and patients.

Cavitary disease has long been recognized as a predictor of poor treatment outcome and as a factor formally associated with the need for longer treatment duration, especially when associated with positive culture at 2 months\(^\text{43,69}\) (see above). In a series of new developments, pulmonary PET–CT and \(\mu\)CT imaging have shown that cavities spread \(M.\) \(tuberculosis\) to other parts of the lungs through the bronchi\(^\text{113,114}\), revealing wide networks of connected lesions with complex morphology, in stark contrast with the oversimplified view that TB granulomases and cavities are isolated spherical structures. The extent of bronchogenic spread, its contribution to disease dissemination, and its impact on treatment outcome in animal models remain to be defined to guide the manipulation of models that better recapitulate this aspect of TB\(^\text{116}\). Thus, targeting treatment not only to cavities but also to airway networks and the bronchial tree might be more important than previously realized to accelerate cure.

**Prioritizing promising drug combinations.** Owing to a growing pipeline of anti-TB drug candidates [FIG. 5a], a new paradigm of pan-TB regimen development has gained momentum over the past 5–10 years. New regimens to treat drug-susceptible, MDR and XDR \(M.\) \(tuberculosis\) infections have become conceivable due to the substantial proportion of drug candidates and recently approved drugs with novel mechanisms of action [FIG. 5b]. Universal regimens would substantially accelerate global efforts to control TB. Given the overwhelming number of potential combinations of three, four and five drugs selected from ten major classes, whether approved or in clinical development, the number one priority is the development of a rationale to predict best performing regimens. So far, the ranking of regimens for clinical trials has been driven by limited preclinical data and could thus be optimized\(^\text{117}\).

Several steps could contribute to a rationale for the prioritization of regimens combining drugs that optimally reach and kill all \(M.\) \(tuberculosis\) bacilli, thereby maximizing the potential to shorten treatment. We can measure how effectively each drug covers the diverse sites of infection, how much is required to inhibit or kill each mycobacterial subpopulation, and whether adequate concentrations are sustained during a typical dosing interval. Algorithms that integrate drug penetration into major lesion compartments, drug potency against intracellular and extracellular persisters at the sites of disease, host immunity, and efficacy in preclinical models can simulate lesion coverage\(^\text{118}\) and prioritize combinations predicted to accelerate sterilization and reduce relapse rates\(^\text{109–122}\). This approach, combined with predictions of synergistic drug combinations, could deliver an affordable number of promising drug combinations to be tested in resource-intensive animal models.
that reproduce features of human pathology not seen in mice. Using an iterative strategy, researchers can identify specific features, read-outs and outcomes that predict treatment shortening and further refine the computational tool (Fig. 4). Concomitant testing of prioritized regimens in early clinical trials using biomarkers predictive of long-term outcome would therefore enable validation of animal models and refinement of the translational platform. This translational approach is in its infancy but holds promise to spare years of clinical development for new pan-TB drug regimens.

Conventional assessment of durable cure of active TB in clinical trials is inherently slow and involves very large patient cohorts followed by long follow-up periods.
Adaptive trial designs that simplify and accelerate both phase II and phase III\textsuperscript{128} have been proposed to evaluate the growing pipeline of drug candidates and leverage the massive efforts dedicated to regimen prioritization using translational platforms that link in silico, in vitro and in vivo data (Supplementary Box 1). To maximize the impact of adaptive designs and rapidly identify drug combinations for progression from phase II to phase III, biomarkers predictive of long-term outcome are sorely needed, yet decades of research have not delivered a ‘magic bullet’. Improved bacteriological read-outs (quantitative, longitudinal and continuous measures that are more sensitive to differences than the traditional 8-week sputum conversion end point) have been proposed and are increasingly adopted in clinical trials\textsuperscript{129}. Recent efforts have focused on PET–CT to distinguish lesions that resolve rapidly, slowly or not at all in response to conventional versus novel treatment regimens\textsuperscript{127}. Key to the success of regimen prioritization, trials should include measurements of drug concentrations to validate the lesion coverage approach for predicting treatment shortening as well as risk stratification algorithms to tailor doses and treatment duration to the extent of disease, immune status, and other validated correlates of poor prognosis\textsuperscript{130}. Overall, many innovative and exploratory development strategies remain to be harmonized and formally endorsed to accelerate and enhance our ability to learn.

**Breaking the tolerance–resistance link.** Bacteria can produce populations of dormant cells that are tolerant to killing by antibiotics. Drug tolerance conferred by slow growth can be genetically encoded or not and sets bacteria on the path to high-level resistance primarily mediated by ‘on-target’ mutations. The discovery of an evolutionary pathway from tolerance to resistance underscores the possibility that treatment strategies that can eliminate tolerant cells to prevent the development of genetic resistance from phenotypically resistant bacterial subpopulations could shorten therapy\textsuperscript{131,132}. Bacteria can also acquire non-canonical mutations that confer survival advantages in the presence of a given antibiotic, that is, an increased level of tolerance to the drug, likely acting as stepping-stones for acquisition of canonical drug resistance. Resource considerations underline the need for prioritization, using validated in vitro assays, drug interaction platforms, such as INDIGO or DiaMOND, pharmacokinetic (PK) and pharmacodynamic (PD) studies in preclinical species, and translational modelling tools, to select drug combinations with the highest potential to reduce treatment duration and improve cure in patients with tuberculosis, thus reducing the number of clinical trial arms to practical dimensions. New strategies, such as adaptive trial designs, doses and treatment duration tailored to patient characteristics, and longitudinal biomarkers of efficacy are required to accelerate the learning cycle, validate the in vitro and in vivo prioritization tools, and refine the computational approaches. Middle panel, top right, adapted from REF.\textsuperscript{188}, Springer Nature Limited. Middle panel, bottom left, adapted from REF.\textsuperscript{189}, Springer Nature Limited. Middle panel, top left, reprinted from REF.\textsuperscript{190}, Springer Nature Limited.
Despite the substantial global population of individuals with subclinical tuberculosis (TB) and the enormous medical need, the knowledge gaps are vast and perhaps more difficult to fill than for active TB due to the nature of latent infection. There is a lack of experimental model systems that fully recapitulate the immune status of the infected individual or Mycobacterium tuberculosis within host physiology,[192] and thus progress has been slower than for active TB. The isoniazid–rifampicin-based recommended regimens were empirically selected for clinical evaluation and have not been compared side-by-side to calibrate model systems. Only observational studies have been completed with individuals who had been in contact with others who are infected with multidrug-resistant (MDR) M. tuberculosis, which suggested that preventive therapy based on second-line drugs may lower the risk of progression to TB disease, and three placebo-controlled trials are ongoing (see the table).

Given the limited breadth of clinical efficacy data available to benchmark latent TB infection (LTBI) in animal models for testing new preventive therapies, one may consider a parallel strategy whereby new drugs or regimens (FDA-approved or EMA-approved, such as levofloxacin and delamanid) are evaluated in clinical trials without prior testing in a preclinical model. If successful, these therapeutic interventions could rapidly translate into the clinic and be integrated into global health policies. Meanwhile, experimental models that accurately recapitulate clinical efficacy and integrate new technologies that provide quantitative and physiological information about bacteria in lesions, could be validated against existing and new clinical data. Optimizing an animal model that reasonably recapitulates subclinical TB carries many pitfalls[192]. The macaque models control infection in a subset of animals, as seen in human TB, and are likely to be a suitable starting point for a preclinical model to evaluate preventive therapy[25,193]. This could go hand in hand with the development of tools to map, track during treatment, and quantify viable bacilli and profile their metabolic status in latent TB granulomas, lymph nodes and other sites of infection.

### Box 1 | Models and trials to test new drugs against reactivation of LTBI

| Drug or drug regimen and duration | Status | Acronym | Patient population | Refs or trial number |
|-----------------------------------|--------|---------|--------------------|----------------------|
| Isoniazid alone for 6 or 9 months, or an isoniazid–rifampicin combination for 2 or 3 months | Recommended by WHO and CDC; considered equivalent though not compared directly in clinical trials | – | Individuals with diagnosed LTBI at risk of reactivation in endemic countries, all individuals with diagnosed LTBI in the USA | 13–16 |
| Rifampicin for 4 months | Recommended by the American Thoracic Society in 2000; higher completion rate than and comparable safety to 9-month isoniazid | – | Children diagnosed with LTBI | 194 |
| Various second-line drugs and duration | Evaluated in observational studies | – | Household contacts (children and/or adults) of patients infected with MDR M. tuberculosis | 195 |
| Levofloxacin versus placebo control for 6 months | Placebo-controlled trial | TB-CHAMP | Children household contacts of patients infected with MDR M. tuberculosis | 196 |
| Levofloxacin versus placebo for 6 months | Placebo-controlled trial | VQUIN | Household contacts of all ages of individuals who are infected with rifampicin-resistant or MDR M. tuberculosis | 197 |
| Delamanid versus isoniazid for 6 months | Placebo-controlled trial | PHOENIx | High risk (individuals positive for HIV-1 or individuals without HIV-1 positivity that are immunosuppressed, and children under 5 years old) household contacts of individuals who are infected with MDR M. tuberculosis | NCT03568383 |

### Subclinical tuberculosis

Mycobacterium tuberculosis infection presenting with mild or no symptoms, where low bacterial burden persists in a quiescent state, can be detected by conventional immune-based assays and can be intermittently culture-positive but spurn smear-negative due to the low bacillary load.

### Mutasome

The protein components that assemble at a DNA lesion in the presence of a stalled replication complex to mediate translesion DNA synthesis in a mutagenic manner.

resistance[13]. In *M. tuberculosis*, several tolerance mechanisms have been suggested to facilitate the emergence of drug resistance: mistranslation[134], alteration of proionate metabolism[135], phase variation in *glpK*[135,136] and hypoxia-induced carbon flux diversion[137–139]. RNase J is disproportionately mutated in drug-resistant clinical *M. tuberculosis* isolates[13] and preliminary results indicate that deletion of the corresponding gene confers increased tolerance to lethal concentrations of several drugs by reducing their killing rate[40]. Disabling the DosRS dormancy regulon through chemical inhibition by artemisinin suppressed tolerance to isoniazid[41]; targeting asymmetric cell division leads to the loss of single-cell heterogeneity and faster killing by vancomycin and rifampicin[42]; and decreasing mistranslation with the aminoglycoside kasugamycin potentiates rifampicin activity in vitro and in mice[42]. Host immune responses may promote drug tolerance through several mechanisms: they apply pressure on bacterial growth, thereby altering drug susceptibility[44]; they shape the microenvironment to which drugs are exposed at the sites where *M. tuberculosis* resides and can lead to pH and oxygen concentrations[44,45] that may reduce (or occasionally enhance) drug activity; and they alter granuloma histopathology in ways that impact drug access[46,47]. Host-directed therapies that target each of these mechanisms have the potential to reduce drug tolerance and resistance[4]. Additional mechanisms of drug tolerance are reviewed elsewhere[47] such as the disproportionate number of toxin–antitoxin systems present in *M. tuberculosis* that mediate stress-induced adaptation, slowing of growth and drug tolerance. These are early-stage and exploratory observations, yet they lend support to the concept of tackling tolerance to prevent resistance. Though not falling under the category of tolerance per se, other indirect mechanisms facilitate the emergence of resistance and could be targeted to prevent or limit it. For example, a preliminary study suggests that disruption of the *ImuB–DnaN* (β-clamp) interaction by griselimycin prevents DnaE2-mediated induced mutagenesis, suggesting that the mycobacterial mutasome might be a good target for novel ‘anti-evolution’ drugs.
aimed at protecting against emergent resistance; inhibition of bacterial factors that promote mutagenesis as an anti-evolution strategy; inhibition of intrabacterial metabolism by promiscuous cytochromes and other enzymes that may constitute a source of induced resistance; and inhibition of nonspecific drug efflux pumps shown to extrude anti-TB drugs.

**Preventing reactivation of LTBI.** Once a validated biomarker signature of incipient and progressing TB has been established to triage patients with LTBI who would benefit from preventive therapy, TB control programmes will need single drugs or regimens that can be administered safely to individuals with LTBI who are not only at risk of reactivation but are also contacts of individuals who are infected with MDR *M. tuberculosis*. The five recommended regimens all contain isoniazid and/or a rifamycin and are thus adequate for these important populations. In addition, individuals with HIV-1 and LTBI should not receive rifampicin if they are treated with antiretroviral agents that are substrates of CYP3A4. More so than for active TB, a universal drug or drug combination is critical as the MDR or XDR status cannot be assessed in LTBI and is only inferred from household contact susceptibility profiling. New pan-TB regimens that successfully shorten treatment of active TB may provide invaluable lessons to tackle persisters in latent TB granulomas and prevent reactivation of LTBI. A 'sterilizing' rationale would help design clinical trials with a better potential to cure subclinical, incipient and progressing TB [BOX 1].

**Conclusion**

The repercussions of the COVID-19 outbreak have already made clear that we are unlikely to reach the targets of the WHO 'end TB strategy', which call for 80% reduction in TB incidence and 90% reduction of TB deaths by 2030 [REF.125]. Even under more favourable circumstances, these goals are often considered an optimistic scenario given the logistical complexities of a 6-month multidrug regimen and the poorer treatment outcomes in the setting of antibiotic-resistant disease. Shorter and more effective therapies could get us a long way towards these millennium goals, but this will take decades if we are to rely on the traditional approach of iterative large clinical trials with small incremental variations in drug regimens. Breakthroughs will come from transformative trial designs and rationally designed regimens with novel mechanisms of action. The success of bedaquiline–pretomanid–linezolid for MDR and XDR *M. tuberculosis* is one promising step in that direction and has provided a backbone for limitless variations that can be explored. We are hopeful that the preclinical and clinical approaches we described in this Review can lead to the selection and evaluation of drug combinations earlier in the development cascade and greatly accelerate the approval of shorter treatment regimens.

Sociological changes, such as breaking down barriers among collections of academia, non-governmental organizations, funders and drug sponsors, favour collaborative actions that intensify the discovery of breakthrough drug candidates. However, truly accelerating drug development will require changes at all levels, from sustainable funding of basic and applied research through modernized clinical trials. Additionally, ultimately, we might end up with more personalized therapy, which would entail broad changes in how we deliver care in most of the world. For now, big challenges remain but change has already come and there is cause for optimism with a healthy dose of realism.

Published online 27 April 2022
33. Sterling, T. R. et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm. Rep. 69, 1–11 (2020).

34. Al, J. W., Buan, O. & Zhang, W. H. Updates on the risk factors for latent tuberculosis reactivation and their management. Emerg. Microbes Infect. 9, 625–628 (2020).

35. Lobue, P. & Menzies, D. Treatment of latent tuberculosis infection: an update. Respir. Intern. 15, 662–665 (2019).

36. Seddon, J. A. et al. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials 19, 693 (2018).

37. Torre-Cisneros, J. et al. Tuberculosis prophylaxis with levofloxacin in aquatic patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin. Infect. Dis. 60, 1642–1649 (2015).

38. Fox, G. J. et al. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUN MDR trial): a protocol for a randomised controlled trial. BMJ Open 10, e035945 (2020).

39. Shah, M. & Dorman, S. E. Latent tuberculosis infection: global prevalence, incidence, and recent advances. Clin. Microbiol. Rev. 28, 385–2270 (2021).

40. Aber, V. R. & Nun, A. J. Short-term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy. Bull. Int. Union Tuberc. 55, 276–280 (1978).

41. Savic, R. M. et al. Defining the optimal dose of rifampicin for latent tuberculosis exposure: exposure-resistance relations from two phase II clinical trials. Clin. Pharmacol. Ther. 102, 521–531 (2017).

42. Frankland, M. F. et al. Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study. Am. J. Respir. Crit. Care Med. 203, 111–119 (2021).

43. Imperial, M. Z. et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat. Med. 24, 1708–1715 (2018).

44. Lange, C. et al. Management of drug-resistant tuberculosis. Lancet 394, 953–966 (2019).

45. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment (WHO, 2019).

46. Hochberg, C. R. Jr, Barry, C. E. 3rd & Lange, C. Treatment of tuberculosis. N. Engl. J. Med. 375, 2149–2160 (2015).

47. Balaban, N. Q. et al. Definitions and guidelines for research on antibiotic persistence. Nat. Rev. Microbiol. 17, 441–448 (2019).

48. Gold, B. & Nathan, C. Targeting phenotypically tolerant Mycobacterium tuberculosis. Microbiol. Spectr. https://doi.org/10.1128/microbiolspec.TTB2-0031-2017 (2017).

49. DHN, N. & Mockel, M. & Manina, G. Phenotypic heterogeneity in Mycobacterium tuberculosis. Microbiol. Spectr. https://doi.org/10.1128/microbiolspec.MCR-0011-2016 (2016).

50. Aldridge, B. B. et al. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science 355, 100–104 (2012).

51. Wakamoto, Y. et al. Dynamic persistence of antibiotic-labile mycobacterial cells lead to variable growth and antibiotic susceptibility. Proc. Natl Acad. Sci. U S A 110, 20558–20563 (2013).

52. Connolly, L. E., Edelstein, P. H. & Ramakrishnan, L. Revealing diverse vulnerabilities of Mycobacterium tuberculosis reveals a host Warburg effect and a dormant transcriptional program. Proc. Natl Acad. Sci. U S A 112, 1223–1227 (2015).

53. Kimmey, J. M. et al. Unique role for ATG5 in mycobacterial growth and division. Proc. Natl Acad. Sci. U S A 110, 20558–20563 (2013).

54. Barry, C. E. & Mayer-Barber, K. D. Signature required: identifying and separating mixed Mycobacterium tuberculosis infections from WGS data. Microb. Genom. 6, m005071 (2020).

55. Cohen, T. et al. Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment control. Clin. Microbiol. Rev. 25, 708–719 (2012).

56. Band, V. I. & Weiss, D. S. Heteroresistance--a cause of unexplained antibiotic treatment failure? PLoS Pathog. 15, e1007726 (2019).

57. Ernst, J. D. Mechanisms of Mycobacterium tuberculosis immune evasion as challenges to vaccine design. Cell Host Microbiol. 24, 34–42 (2018).

58. Shi, Q., Wang, L., Liu, C. H. & Ge, B. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cell Mol. Microbiol. 17, 901–915 (2020).

59. Pridouz, B. et al. The association between sterilizing activity and drug distribution and tuberculosis lesions. Nat. Med. 21, 1225–1227 (2015).

60. Sarathy, J. P. & Dartois, V. Caseum: a niche for Mycobacterium tuberculosis drug tolerant persisters. Clin. Microbiol. Rev. 33, e00159-19 (2020).

61. Moshabela, G. T. de, The, J. T. & Warner, D. F. Mycobacterium tuberculosis: transcriptional metabolic landscape. PLoS Biol. https://doi.org/10.1128/microbiolspec.CPS-0067-2019 (2019).

62. Hawn, T. R., Shah, J. A. & Kalman, D. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol. Rev. 264, 344–352 (2015).

63. Liu, R. P. et al. Transcriptional characterization of tuberculosis sputum reveals a host Warburg effect and microbial cholesterol catabolism. mBio 12, e01766-21 (2021).

64. Larkin-Ford, J. et al. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. Cell Syst. 12, 1046–1056 e7 (2021).

65. Bosch, B. et al. Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis. Cell 186, 4079–4095 e24 (2021).

66. Rock, J. M. et al. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nat. Microbiol. 2, 16274 (2017).

67. Okoli, M., Kuru, N., Bicak, E., Larkin-Ford, J. & Aldridge, B. E. Efficient factorizing of high-order drug interactions in Mycobacterium tuberculosis. Sci. Adv. 3, e1701881 (2017).

68. Ma, S. et al. Transcriptional regulators of drug synergy and clinical regimen efficacy against tuberculosis. mBio 10, e02627-19 (2019).

69. Clemens, D. L. et al. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. PLoS ONE 14, e0215607 (2019).

70. Lee, B. Y. et al. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both neutral and high susceptibility. PLoS ONE 13, e0207469 (2018).

71. Band, V. I. et al. Antibiotic combinations that exploit heterogeneous efficacy in pulmonary tuberculosis infection. Nat. Microbiol. 4, 1627–1635 (2019).

72. Peterson, E. R. et al. M. saur, D. Sherman, R. & Baliga, N. S. Network analysis identifies Rv0324 and Rv0880 as...
regulators of bedaquiline tolerance in Mycobacterium tuberculosis. Nat. Microbiol. 1, 16078 (2016).

109. Walter, N. D. et al. Mycobacterium tuberculosis precursor RNA as a measure of treatment-shortening activity of drugs and regimens. Nat. Commun. 12, 2899 (2021).

110. Gideon, H. P. et al. Multimodal profiling of lung granulomas reveals core correlates of tuberculosis control. bioRxiv https://doi.org/10.1101/2020.10.20.352492 (2021).

Preprint at.

111. Donkelaar, R. et al. Phenotypic and visualization of live Mycobacterium tuberculosis bacilli from tuberculosis patient bioaerosols. PLoS Pathog. 17, e1009262 (2021).

112. Berry, M. P. et al. An interferon-γ-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 975–977 (2010).

113. Wells, G. et al. The influence of drug regimens, towards bundling of preclinical data. Tuberculosis 204, 585–595 (2021).

114. Chen, R. Y. et al. Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis. Lancet Microbe 2, e15–e52 (2021).

115. Xie, Y. L. et al. Fourteen-day PET/CT imaging to determine antibiotic tolerance in mycobacteria via paradoxical changes in rpoB transcription. Nat. Commun. 9, 4218 (2018).

116. Bellerose, M. M. et al. Common variants in the glycerol kinase gene reduce tuberculosis drug efficacy. Antimicrob. Agents Chemother. 60, 5665–5673 (2016).

117. Safi, H. et al. Phase variation in Mycobacterium tuberculosis gipk produces transiently heritable drug tolerance. Proc. Natl Acad. Sci. USA 116, 19656–19661 (2019).

118. Lee, J. J. et al. Transient drug-tolerance and permanent drug resistance rely on the trehalose-6-phosphate shift of the human tuberculous lung reveals remarkable heterogeneity in 3D granuloma morphology. Am. J. Respir. Crit. Care Med. 204, 1095–1102 (2021).

119. Libardo, J., Boshoff, H. I. & Barry, C. E. 3rd The interspecies nature of the TB “granuloma”? Am. J. Respir. Crit. Care Med. 204, 505–507 (2021).

120. Martini, M. C. et al. Loss of RNase J leads to multi-drug resistance in Mycobacterium tuberculosis. Nat. Commun. 5, 5782–5789 (2014).

121. Lee, R. E. et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat. Med. 16, 152–158 (2010).

122. Laws, M. E. et al. Two-drug resistance and the effect of machine learning on tuberculosis drug susceptibility testing. J. Bacteriol. 164, 103–105 (2010).

123. Christophe, T., Ewann, F., Jeon, H. K., Cechetto, J. & Duncan, K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 143, 717–731 (2022).

124. Galon, F. et al. The role of RtbMed-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc. Natl Acad. Sci. USA 100, 10206–10211 (2003).

125. Bethes, J. C., Lyke, P. T., Robb, L. C., McAdam, R. A. & Duncan, K. Evaluation of an antibacterial screening model of Mycobacterium tuberculosis persistence by gene expression profiling. Mol. Microbiol. 63, 437–450 (2007).

126. Kaur, S. et al. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem. Biol. 8, 2224–2234 (2013).

127. Dahiya, L. S. et al. Growth of M. tuberculosis H37Rv in vitro: an in-depth study of the bacterium’s growth and metabolic properties. Int. J. Antimicrob. Agents 57, 689–704 (2021).
181. Mukamolova, G. V., Tourapov, O., Malkin, J., Wentmann, G. & Barer, M. R. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. *Am. J. Respir. Crit. Care Med.* **181**, 174–180 (2010).

182. Lipworth, S. et al. Defining dormancy in mycobacterial disease. *Tuberculosis* **99**, 131–142 (2016).

183. Shteyn, G. S., Fromoulis, S. G. & Cho, S. New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. *Transl. Res.* **220**, 68–97 (2020).

184. Singh, R. et al. PA-824 kills nonreplicating *Mycobacterium tuberculosis* by intracellular NO release. *Science* **322**, 1392–1395 (2008).

185. Robertson, G. T. et al. Comparative analysis of pharmacodynamics in the C57BL/6J mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBZT169, and OPC-167852. *Antimicrob. Agents Chemother.* **65**, e0058321 (2021).

186. Tenorio, D. et al. First-time-in-human study and prediction of early bactericidal activity for GSK3036656, a potent leucyl-tRNA synthetase inhibitor for tuberculosis treatment. *Antimicrob. Agents Chemother.* **63**, e00240-19 (2020).

187. Zumbi, A., Nahid, P. & Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens. *Nat. Rev. Drug Discov.* **12**, 388–404 (2013).

188. Rawson, T. M. et al. Optimizing antimicrobial use: challenges, advances and opportunities. *Nat. Rev. Microbiol.* **19**, 747–758 (2021).

189. Roen, R., Bollenbach, T. & Andersson, D. I. The physiology and genetics of bacterial responses to antibiotic combinations. *Nat. Rev. Microbiol.* https://doi.org/10.1038/s41579-022-00700-5 (2022).

190. Tyers, M. & Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. *Nat. Rev. Microbiol.* **17**, 141–155 (2019).

191. Robertson, B. D. et al. Detection and treatment of subclinical tuberculosis. *Tuberculosis* **92**, 447–452 (2012).

192. Vernon, A. & Bishai, W. Modeling treatment of latent tuberculosis: shortening the leap of faith? *Am. J. Respir. Crit. Care Med.* **201**, 405–406 (2020).

193. Bucsan, A. N., Mehra, S., Khader, S. A. & Kaushal, D. The current state of animal models and genomic approaches towards identifying and validating molecular determinants of *Mycobacterium tuberculosis* infection and tuberculosis disease. *Pathog. Dis.* **77**, ftz037 (2019).

194. Oh, C. E. & Menzies, D. Four months of rifampicin monotherapy for latent tuberculosis infection in children. *Clin. Exp. Pediatr.* https://doi.org/10.3345/cep.2021.01186 (2021).

195. Fox, G. J. et al. Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. *Clin. Microbiol. Infect.* **23**, 147–153 (2017).

Acknowledgements

The authors thank B. B. Aldridge and T. Dick for stimulating discussions. Support for work in the authors’ laboratories was provided by grants INV-009173 and INV-004704 from the Bill and Melinda Gates Foundation and grant U19AI142735 from the National Institutes of Health.